Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in the United States, BioCrowd.IO addresses the funding crisis in clinical and translational research. The firm focuses on raising milestone-based capital for hospitals, universities, and patient communities. They manage a portfolio of six companies and aim to unlock capital from various funding sources.
BioCrowd.IO invests between $250K and $900K in biotech, specifically targeting clinical research projects. Their investment strategy emphasizes alternative funding sources, including Donor-Advised Funds and venture philanthropy, particularly for R1 and R2 universities and hospital research organizations. The firm aims to bridge the gap left by decreasing federal funding in the biotech sector.
BioCrowd.IO's portfolio includes notable projects such as The Role of Cancer Stem Cells in Cancer Treatment ($250,000), Research on Neuropsychiatric Disorder ($500,000), Active Immunotherapy for Acute Lymphoblastic Leukemia ($370,000), Research on Nephropathic Cystinosis ($850,000), The Real Science Behind the Billionaire Pursuit of Immortality ($550,000), and Developing a New Type of Treatment for Leukaemia ($900,000).
Submit through their form at https://www.biocrowd.com/contact-us.
BioCrowd.IO typically participates in funding rounds but does not always lead them. Their focus is on providing milestone-based capital to support clinical research.
BioCrowd.IO evaluates follow-on investments on a case-by-case basis, depending on the progress and needs of the projects they support.
The specific size of BioCrowd.IO's current fund is not publicly disclosed, but they provide investments ranging from $250K to $900K.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.